Bexarotene gel: A food and drug administration - Approved skin-directed therapy for early-stage cutaneous T-cell lymphoma

Archives of Dermatology

Volumn 138, Issue 3, 2002, Pages 398-399

  Liu, Howard L ^a   Kim, Youn H ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CARMUSTINE; CHLORMETHINE; PSORALEN;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DOSE RESPONSE; DRUG ABSORPTION; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; ELECTRON BEAM; ERYTHEMA; FOOD AND DRUG ADMINISTRATION; GEL; HUMAN; IMMUNOMODULATION; MYCOSIS FUNGOIDES; NONHUMAN; PAIN; PHOTOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; SKIN IRRITATION; SKIN LYMPHOMA; T CELL LYMPHOMA; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; ULTRAVIOLET B RADIATION;

ANTICARCINOGENIC AGENTS; DRUG APPROVAL; GELS; HUMANS; LYMPHOMA, T-CELL; NEOPLASM STAGING; SKIN NEOPLASMS; TETRAHYDRONAPHTHALENES;

EID: 0036124065     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (6)

1. Mycosis fungoides and the Sezary syndrome
2. Clinical stage IA (limited patch and plague) mycosis fungoides: A long-term outcome analysis
3. Clinical characteristics and outcome of patients with extracutaneous mycosis fungoides
4. A new rexinoid for cutaneous T-cell lymphoma
5. Bexarotene ligand pharmaceuticals
6. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma